These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 27129152

  • 1. Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.
    Severson TM, Nevedomskaya E, Peeters J, Kuilman T, Krijgsman O, van Rossum A, Droog M, Kim Y, Koornstra R, Beumer I, Glas AM, Peeper D, Wesseling J, Simon IM, Wessels L, Linn SC, Zwart W.
    Oncotarget; 2016 Jun 07; 7(23):33901-18. PubMed ID: 27129152
    [Abstract] [Full Text] [Related]

  • 2. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
    Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W.
    Cancer Res; 2016 Jul 01; 76(13):3773-84. PubMed ID: 27197147
    [Abstract] [Full Text] [Related]

  • 3. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
    Jiang G, Wang X, Sheng D, Zhou L, Liu Y, Xu C, Liu S, Zhang J.
    Theranostics; 2019 Jul 01; 9(22):6501-6516. PubMed ID: 31588232
    [Abstract] [Full Text] [Related]

  • 4. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.
    Kong SL, Li G, Loh SL, Sung WK, Liu ET.
    Mol Syst Biol; 2011 Aug 30; 7():526. PubMed ID: 21878914
    [Abstract] [Full Text] [Related]

  • 5. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
    Yamaguchi N, Nakayama Y, Yamaguchi N.
    J Biol Chem; 2017 May 19; 292(20):8136-8148. PubMed ID: 28270510
    [Abstract] [Full Text] [Related]

  • 6. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS, Li Y, Zhang H, Zhang D, Zhang XB, Wang X, Yu Y.
    Theranostics; 2020 May 19; 10(23):10729-10742. PubMed ID: 32929377
    [Abstract] [Full Text] [Related]

  • 7. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
    Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP.
    Mol Cancer Res; 2014 Dec 19; 12(12):1829-39. PubMed ID: 25100862
    [Abstract] [Full Text] [Related]

  • 8. Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.
    Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits MJ, Nederlof PM, van Boven HH, Linn SC, van Leeuwen FE, Wessels LF, Zwart W.
    Proc Natl Acad Sci U S A; 2017 Feb 21; 114(8):E1316-E1325. PubMed ID: 28167798
    [Abstract] [Full Text] [Related]

  • 9. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.
    Breast Cancer Res Treat; 2010 Jul 21; 122(2):395-407. PubMed ID: 19847644
    [Abstract] [Full Text] [Related]

  • 10. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.
    Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, Srinivasan S, Nowak J, Izard T, Rangarajan ES, Carlson KE, Katzenellenbogen JA, Yao XQ, Grant BJ, Leong HS, Lin CY, Frasor J, Nettles KW, Glass CK.
    Mol Cell; 2017 Mar 16; 65(6):1122-1135.e5. PubMed ID: 28306507
    [Abstract] [Full Text] [Related]

  • 11. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.
    Mol Cancer Res; 2008 Aug 16; 6(8):1347-55. PubMed ID: 18708366
    [Abstract] [Full Text] [Related]

  • 12. Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers.
    Salvati A, Giurato G, Lamberti J, Terenzi I, Crescenzo L, Melone V, Palo L, Giordano A, Sabbatino F, Roscigno G, Quintavalle C, Condorelli G, Rizzo F, Tarallo R, Nassa G, Weisz A.
    Mol Cancer; 2024 Aug 07; 23(1):160. PubMed ID: 39113071
    [Abstract] [Full Text] [Related]

  • 13. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.
    Singh K, Munuganti RSN, Lallous N, Dalal K, Yoon JS, Sharma A, Yamazaki T, Cherkasov A, Rennie PS.
    Int J Mol Sci; 2018 Feb 15; 19(2):. PubMed ID: 29462880
    [Abstract] [Full Text] [Related]

  • 14. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.
    Endocr Relat Cancer; 2006 Dec 15; 13(4):1121-33. PubMed ID: 17158758
    [Abstract] [Full Text] [Related]

  • 15. Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications.
    Meeran SM, Patel SN, Li Y, Shukla S, Tollefsbol TO.
    PLoS One; 2012 Dec 15; 7(5):e37748. PubMed ID: 22662208
    [Abstract] [Full Text] [Related]

  • 16. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
    Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.
    Horm Cancer; 2012 Aug 15; 3(4):147-59. PubMed ID: 22476979
    [Abstract] [Full Text] [Related]

  • 17. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
    Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, Barry S, Crnogorac-Jurcevic T, Martin LA, Dowsett M, Charles Coombes R, Kamalati T, Ali S, Buluwela L.
    Breast Cancer Res Treat; 2011 Jul 15; 128(2):357-68. PubMed ID: 20730598
    [Abstract] [Full Text] [Related]

  • 18. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
    Thewes V, Simon R, Schroeter P, Schlotter M, Anzeneder T, Büttner R, Benes V, Sauter G, Burwinkel B, Nicholson RI, Sinn HP, Schneeweiss A, Deuschle U, Zapatka M, Heck S, Lichter P.
    Cancer Res; 2015 Feb 15; 75(4):720-31. PubMed ID: 25643697
    [Abstract] [Full Text] [Related]

  • 19. Loss of Estrogen-Regulated MIR135A1 at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer.
    Zhang W, Wu M, Chong QY, Zhang M, Zhang X, Hu L, Zhong Y, Qian P, Kong X, Tan S, Li G, Ding K, Lobie PE, Zhu T.
    Cancer Res; 2018 Sep 01; 78(17):4915-4928. PubMed ID: 29945962
    [Abstract] [Full Text] [Related]

  • 20. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
    McCune K, Bhat-Nakshatri P, Thorat MA, Nephew KP, Badve S, Nakshatri H.
    Cancer Res; 2010 Jan 15; 70(2):685-96. PubMed ID: 20068169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.